Study of a new drug for advanced ovarian cancer and other solid tumors
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This study tests an experimental drug called TJ102 for people with advanced ovarian cancer or other solid tumors that have grown despite prior treatments. It aims to see if the drug is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced or metastatic high-grade serous ovarian cancer, or cancer of the fallopian tube or peritoneum, that cannot be cured with surgery or radiation.
- Your cancer has grown after your most recent treatment.
- You have received at least one but no more than four prior lines of chemotherapy for advanced disease.
- You have been treated with a platinum-based chemotherapy (like carboplatin or cisplatin).
- You are 18 years or older.
- You are generally able to care for yourself (ECOG performance status 0 or 1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug (DC05F01) for people with ovarian cancer that has come back after platinum treatment, or for those with other advanced solid tumors that haven't responded to standard therapies. It aims to see if the drug is safe and effective.
This trial tests a new drug called ABBV901, given alone or with other anticancer drugs, for people with advanced ovarian, fallopian tube, or primary peritoneal cancer. The goal is to see how well it works and how it affects the body.
This study tests a new drug called TUB-040 for people with ovarian cancer that has stopped responding to platinum chemotherapy, or with a type of lung cancer that has returned or spread. The drug is designed to target cancer cells and deliver a powerful anti-cancer agent directly to them, potentially slowing the disease.
This study tests a new medicine called TUB-040, given together with standard ovarian cancer drugs like carboplatin and bevacizumab. It is for women with ovarian cancer that has returned after responding to platinum-based chemotherapy and is growing again. The goal is to see if this combination can help control the cancer.
This study tests a drug called mirvetuximab soravtansine (MIRV) for women with ovarian, fallopian tube, or primary peritoneal cancer that has not responded to recent treatment. The drug targets a specific protein (FRα) found on some cancer cells, and the study will see how well it works in real-world settings.
This study tests a new investigational drug called JSKN003 for people with ovarian cancer that has stopped responding to standard chemotherapy. The goal is to see if this drug can help shrink tumors and slow down the cancer's growth.
Hear when a new Ovarian cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.